Halozyme Therapeutics, Inc. $HALO Shares Sold by Hsbc Holdings PLC

Key Points

• Hsbc Holdings PLC sold 4,961 shares of Halozyme Therapeutics, reducing its holdings by 51.6% to 4,654 shares valued at $297,000.
• Other institutional investors have also adjusted their positions, with Stifel Financial Corp increasing its stake by 79.7% during the fourth quarter.
• Halozyme's recent earnings report revealed an EPS of $1.54, exceeding analyst expectations and indicating a 40.8% increase in revenue year-over-year.

Hsbc Holdings PLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 51.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,654 shares of the biopharmaceutical company's stock after selling 4,961 shares during the period. Hsbc Holdings PLC's holdings in Halozyme Therapeutics were worth $297,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Congress Asset Management Co. raised its stake in Halozyme Therapeutics by 8.8% during the 1st quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company's stock valued at $136,088,000 after purchasing an additional 172,971 shares during the period. Dimensional Fund Advisors LP grew its position in Halozyme Therapeutics by 4.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company's stock worth $129,478,000 after acquiring an additional 95,600 shares during the period. TD Asset Management Inc raised its stake in shares of Halozyme Therapeutics by 5.8% in the first quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company's stock valued at $92,642,000 after acquiring an additional 79,708 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in Halozyme Therapeutics by 27.3% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company's stock valued at $72,107,000 after buying an additional 242,167 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Halozyme Therapeutics by 3.4% during the first quarter. American Century Companies Inc. now owns 895,412 shares of the biopharmaceutical company's stock worth $57,136,000 after buying an additional 29,046 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO stock traded up $0.57 during trading on Monday, hitting $75.50. 772,542 shares of the company traded hands, compared to its average volume of 1,967,870. The company has a market cap of $8.83 billion, a PE ratio of 17.28, a P/E/G ratio of 0.41 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $76.28. The stock's 50-day simple moving average is $62.80 and its 200 day simple moving average is $59.84. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company's revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the business posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a report on Wednesday, August 6th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a research report on Tuesday, May 13th. Finally, The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $67.11.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the sale, the director owned 46,952 shares of the company's stock, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $46,598,493.69. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 104,000 shares of company stock worth $6,316,120 over the last three months. 2.90% of the stock is owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.